Jaguar Animal Health (JAGX) Given Media Impact Rating of 0.19
Media headlines about Jaguar Animal Health (NASDAQ:JAGX) have been trending somewhat positive recently, Alpha One Sentiment reports. The research group, a unit of Accern, identifies negative and positive news coverage by reviewing more than 20 million blog and news sources. Alpha One ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Jaguar Animal Health earned a coverage optimism score of 0.19 on Alpha One’s scale. Alpha One also assigned headlines about the biotechnology company an impact score of 0 out of 100, meaning that recent news coverage is extremely unlikely to have an effect on the stock’s share price in the immediate future.
Jaguar Animal Health (NASDAQ:JAGX) traded down 3.43% during trading on Friday, reaching $0.78. 127,882 shares of the company were exchanged. The firm’s market cap is $10.93 million. The firm has a 50-day moving average of $1.00 and a 200-day moving average of $0.87. Jaguar Animal Health has a 52-week low of $0.50 and a 52-week high of $3.79.
Separately, Zacks Investment Research raised shares of Jaguar Animal Health from a “sell” rating to a “hold” rating in a research note on Tuesday, January 10th.
Jaguar Animal Health Company Profile
Jaguar Animal Health, Inc is an animal health company. It is focused on developing and commercializing gastrointestinal products for companion and production animals, foals, and horses. Canalevia is its prescription drug product candidate, intended for treatment of various forms of diarrhea in dogs. Canalevia is a canine-specific formulation of crofelemer, an active pharmaceutical ingredient (API) isolated and purified from the Croton lechleri tree.
Receive News & Ratings for Jaguar Animal Health Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jaguar Animal Health Inc and related companies with MarketBeat.com's FREE daily email newsletter.